Clearpoint Neuro Inc

NASDAQ CLPT

Data sourced from

and

Download Data

Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities 5 year CAGR for the quarter ending March 31, 2024: -2.67%

Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities 5 year CAGR is -2.67% for the quarter ending March 31, 2024, a -114.23% change year over year. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2023 was -0.94, a 12.68% change year over year.
Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2022 was -1.07, a -57.37% change year over year.
Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2021 was -0.68, a -6.70% change year over year.
Clearpoint Neuro Inc Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2020 was -0.64, a -120.60% change year over year.

NASDAQ: CLPT

Clearpoint Neuro Inc

CEO	Mr. Joseph Michael Burnett
IPO Date	Feb. 12, 2020
Location	United States
Headquarters	120 S. Sierra Avenue, Solana Beach, CA, United States, 92075
Employees	107
Sector	Healthcare
Industry	Medical devices

Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Key trends